Dr. Roboz on Evolving Paradigms in AML Treatment
August 25th 2017Gail Roboz, MD, a professor of medicine and director of the Clinical and Translational Leukemia Program at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses evolving paradigms in treatment of patients with acute myeloid leukemia (AML).
Dr. Leonard on Precision Medicine in Hematologic Malignancies
August 24th 2017John P. Leonard, MD, associate dean of Clinical Research, interim chair of the Department of Medicine, Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the advance of precision medicine across hematologic malignancies.
Dr. Martin on Potential of Immunotherapy in MCL Landscape
August 18th 2017Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the potential of modern immunotherapies in the landscape of mantle cell lymphoma (MCL).
Dr. Furman on Considering Factors for Upfront Therapy in CLL
August 15th 2017Richard R. Furman, MD, Morton Coleman, M.D. Distinguished Associate Professor of Medicine, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses factors to consider when choosing upfront therapy for patients with chronic lymphocytic leukemia (CLL).
Dr. Martin on ASCT-Related Toxicities for Patients With MCL
August 8th 2017Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the toxicities related to stem cell transplantation for patients with mantle cell lymphoma (MCL).
Dr. Furman on Second-Generation BTK Inhibitors in CLL
August 3rd 2017Richard R. Furman, MD, Morton Coleman, M.D. Distinguished Associate Professor of Medicine, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses second-generation BTK inhibitors, such as acalabrutinib and BGB-3111 in chronic lymphocytic leukemia (CLL).
Dr. Martin on the Role of Transplant in Mantle Cell Lymphoma
May 23rd 2017Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the role of transplant in the field of mantle cell lymphoma (MCL).
Dr. Furman on Utility of Prognostic Markers in CLL
May 12th 2017Richard R. Furman, MD, Morton Coleman, M.D. Distinguished Associate Professor of Medicine, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the use of prognostic markers in the treatment of patients with chronic lymphocytic leukemia (CLL).
Dr. Niesvizky on Exciting Changes in the Multiple Myeloma Landscape
May 8th 2017Ruben Niesvizky, MD, professor of medicine, Joan and Sanford I. Weill Department of Medicine , Weill Cornell Medical College/NewYork-Presbyterian Hospital, discusses some of the exciting changes that have occurred in the field of multiple myeloma.
Dr. Martin on Patient Preferences With MCL Treatment
May 5th 2017Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian, discusses preferences patients have for their treatment of mantle cell lymphoma (MCL).
Dr. Leonard on Emergence of CAR T-cell Therapy in Hematologic Cancers
May 5th 2017John P. Leonard, MD, associate dean of Clinical Research, interim chair of the Department of Medicine, Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the emergence and potential of chimeric antigen receptor (CAR) T-cell therapy across hematologic malignancies.
Dr. Tagawa Discusses the Development of Immunotherapy in Urothelial Cancer
April 14th 2017Scott T. Tagawa, MD, MS, assistant professor of Medicine, medical director, Genitourinary Oncology Research Program, assistant attending physician, New York-Presbyterian Hospital, discusses the development of immunotherapy for patients with urothelial cancer.
There's an App for That: Keeping Patients and Physicians on Track
September 1st 2016In a pilot study, funded by both the Society for Surgery of the Alimentary Tract and The Center for Advanced Digestive Care, researchers at Weill Cornell Medicine are testing a new mobile app that could help transform postoperative patient monitoring.
Dr. Madoff on Selecting Patients With HCC Appropriate for Minimally Invasive Therapy
March 14th 2016David C. Madoff, MD, professor of Radiology, vice chairman for Academic Affairs at Weill Cornell Medicine, discusses selecting patients with hepatocellular carcinoma who are candidates for minimally invasive therapy.